For the first quarter of 2017, the dialysis business for Fresenius Medical Care North America (FMCNA) grew by 14% (10% at constant currency). Quarterly growth was influenced by the positive effect of an agreement with the US Departments of Veterans Affairs (VA) and Justice for a settlement for underpayment, a favorable impact from commercial payers, and an increased number of treatments. Dialysis care revenue for the quarter rose to $2.65 billion from $2.32 billion from the first quarter of 2017 to the first quarter of 2016.
DaVita had overall patient service revenues of $2.6 billion in the first quarter of 2017, compared with first quarter 2016 revenues of $2.48 billion, a 5% increase. DaVita also noted a favorable impact from the VA settlement in its quarterly announcement.
According to their respective web sites, FMCNA delivered care to 188,987 patients in 2016 and DaVita to 188,000 patients by December 31, 2016. However, at the end of the first quarter of 2017, DaVita reported providing services to “approximately 205,900 patients at 2544 dialysis centers (2382 in the US, or 94% of DaVita centers).”
In the first quarter of 2017, DaVita opened 24 new dialysis centers and acquired 12 dialysis centers in the US, as well as opening five new dialysis centers and acquiring three centers outside the US.
The third largest US dialysis service provider is US Renal, based in Plano, Texas, which serves more than 23,000 patients across 31 states and the Territory of Guam.